Decision Resources, Inc., Jan 2010, Pages: 46
to grow by consolidation or those looking to cement a stronger position in specialty drugs, emergingmarkets, and biosimilars/generics. In this report, we assess the health of Midsize Pharma and examine
JZMed Inc., Oct 2011, Pages: 215
.
- At the same time, all global major pharma companies also increasingly pay serious attention to the emergingmarkets. They are currently not only focusing on expanding their market space in the emerging
JZMed Inc., Feb 2012, Pages: 127
companies
3.3 Analysis of current outsourcing strategies of major pharma companies in emergingmarkets
3.4 Outsourcing demands by local Asian biotech companies
3.5 Analysis of current China outsourcing
Business Insights, Dec 2010, Pages: 215
Innovative Drug Discovery in EmergingMarketsEmergingmarkets have represented important growth opportunities for the global pharmaceutical industry, but it has been unclear the extent to which
Ovum, Nov 2010, Pages: 29
, outsourcing will continue to increase
- CROs will have a significant impact on the transformation of the R&D landscape
- Emergingmarkets are hotspots for outsourcing pharmaR&D and manufacturing
Datamonitor, Dec 2009, Pages: 17
model: Pharma 2.0, new R&D models embrace biotechnology and biomedical research and the future success of pharma relies on the emergingmarkets.
As the life sciences industry moves into its next phase
Ovum, Sep 2010, Pages: 62
as a whole, they will better comprehend the dynamics of the APAC markets and how the developed and emergingpharma industries fit into their customers' global strategies.The Asia-Pacific life sciences industry
Credit Analysis & Research Limited, Dec 2011, Pages: 133
Pharma Industry
a) Emphasis on pharmaR&D
b) In-licensing agreement to augment business
c) Consolidation and diversification of existing pharma players
d) Emerging therapeutic segments and trend
e
Datamonitor, March 2010, Pages: 257
regulatory processes
New healthcare initiatives in the emergingmarkets are tackling growing costs
Brazil’s ANVISA may hamper the domestics growth of multinational pharma companies
Russia enhances
JZMed Inc., May 2011, Pages: 230
pharma companies in China
2.7 Roles of multinational drug companies in Chinese-made finished drugs marketed overseas
2.8 Multinational drug companies strengthening their manufacturing and marketing
Decision Resources, Inc., Sep 2011
of the fact that the amino acid sequence of the originator biologic has gone off patent. In today’s pharmaceutical markets, companies need to invest their precious R&D resources in developing value-added
Datamonitor, March 2010, Pages: 114
Pharmaceutical Licensing Overview Introduction
Big Pharma continues to restructure its internal R&D departments as part of widespread cost-cutting measures to help reduce the impact of the impending
Pharma-Reports, Jan 2012, Pages: 102
of Patent Applications Files by Big Pharma
Decline on R&D Investment Returns
Patent Losses for Blockbuster Drug
Decline in Sales Following Patent Expirations
Advantage for Generic Companies
Low R
Business Insights, Sep 2007, Pages: 141
to China, assess future growth opportunities within the domestic pharma and biotech markets and deploy outsourced R&D more effectively with this new report.
Key findings...
-Chinese sales of Western-style
Decision Resources, Inc., Dec 2009, Pages: 25
is substantially greater than in most other emergingmarkets, the pharmaceutical market is maintaining double-digit growth rates, and consumers have a strong preference for familiar branded drugs. In addition
Business Insights, Jan 2010, Pages: 151
- Identify points of convergence of the pharma, diagnostic and food and drinks markets which may offer new opportunities for co development
- Review market drivers regarding the adoption of nutrigenomic
Global Industry Analysts, Inc., Jan 2012, Pages: 443
PharmaR&D Pipelines are Drying Up 23
Legal and Infrastructure Hurdles in EmergingMarkets - A
Concern for Global Pharma Industry 23
4. COMPETITIVE LANDSCAPE 24
Consolidation Activity Remains Rife 24
JZMed Inc., Oct 2009, Pages: 230
key roles in this Chinese industry. The first group contains those top tier pharma companies. However, within this group of companies only a small fraction of them are conducting truly innovative drug R
